Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SOUTH SAN FRANCISCO, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced the appointment of Rob...
-
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President...
-
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results...
-
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, Satsuma...
-
Completed upsized initial public offering of $90.8 million in gross proceeds Dosed first patient in Phase 3 EMERGE™ efficacy trial of STS101 for the acute treatment of migraine Presented STS101...